All News

Urologist Garrett D. Pohlman, MD, reflects on the benign prostatic hyperplasia offerings from the 2025 American Urological Association Annual Meeting.

The data are to be presented at an upcoming medical conference.

"This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.

Patient-reported pain scores were significantly improved with stent omission.

“We do not feel that our results undermine the importance of fluid intake for stone prevention," says Alana C. Desai, MD.

Data showed that physical function and self-reported frailty assessments were poorly correlated.

The Oncologic Drugs Advisory Committee meeting is scheduled for May 21, 2025.

Initial study results may be available as soon as the first half of 2026.

Jennifer Miles-Thomas, MD, URPS, MBA, discusses the AUA's legislative priorities along with issues in medicine related to artificial intelligence.

The sBLA for NAI was submitted to the FDA in March 2025.

Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.

"Developing a relationship with your legislator is just as important at the state level as it is at the federal level," says Hans Arora, MD, PhD.

Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.

These results are expected to support submission of the Hugo system to the FDA for use in urologic procedures.

Data showed an overall CR rate of 82.4%.

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.

Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.

Twelve-month physical functioning scores were comparable between the radical cystectomy arm and the bladder-sparing therapy arm.

The investigators reported an overall incidence of AEs of 29.6%.

A recap of the FDA submissions and regulatory decisions in urology from April 2025.

A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.

Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

Discover groundbreaking insights in urology as Larry Lipshultz, MD, shares innovative research and strategies for male fertility challenges.

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

The study population was able to avoid 952 cystoscopies and 70 CT scans, according to the investigators.

No device- or procedure-related serious AEs were observed through 12 months across the entire study population

Kathrins discusses the intricacies of leading a clinical trial and why "negative" trials are important to informing care strategies.